Scott Bluni is a Senior Principal with Kacvinsky Daisak Bluni (KDB), focusing on patent matters. His practice includes patent portfolio management and strategic counseling, licensing, product clearance, prosecution, deal diligence and litigation. Although Scott represents clients across a broad range of industries and technologies, he has a particular expertise in medical technologies and life science patent matters.
Prior to Kacvinsky Daisak Bluni, Scott was a partner and co-chair of the intellectual property group at Bingham McCutchen LLP, a large international law firm. Previously, Scott was vice president and cardiovascular chief patent counsel at Boston Scientific Corporation, a major global medical device company. Scott began his legal career as a patent examiner with the United States Patent and Trademark Office while attending evening law school, after which he was an associate at Kenyon & Kenyon, an intellectual property boutique, in Washington, D.C.
Scott’s clients range from startups to Fortune 20 companies to research universities. For larger companies, he has handled all IP-related aspects of numerous significant transactional matters valued at several hundred million dollars, and has managed litigation matters involving patented products having annual sales into the billions of dollars. He is also regularly called upon for product clearance and opinion matters. For smaller clients, Scott is often the acting general counsel and typically focuses on invention mining, portfolio development and management, and technology licensing. For universities, Scott helps develop and implement spinout and out-licensing strategies.
Scott earned his JD at George Washington University Law School, has PhD and MS degrees from Lehigh University in Materials Science and Engineering, and a BS degree in Metallurgical Engineering from Lafayette College. He is a registered patent attorney, and admitted to practice law in Massachusetts and New York.